News and commentary from the psychiatry world
— News and commentary from the psychiatry world
June 24, 2026
• 2 min read
Topline data showed that a single dose of an investigational LSD-based pill (DT120) met primary and key secondary endpoints in a phase III trial of adults with major depressive disorder, developer Definium Therapeutics said.
Despite a recent executive order fast-tracking psychedelic drug research, drugmakers don't expect third-party manufacturers to boost their psychedelic services right now. (Endpoints News)
Definium LSD therapy helped patients with major depression in late-stage trial
LSD Just Passed Its Biggest Test Yet for Treating Depression
Definium reports Phase 3 hit for LSD drug in severe form of depression
Definium Soars As Much As 50% After LSD-Based Depression Drug Meets Late-Stage Clinical Trial Goal
Biotech Goes Sky-High After LSD Drug Treats Depression
Psychedelic Stocks Could Explode Higher
Wall Street investors rush into psychedelic drugs | The Jerusalem Post
To Wall Street, psychedelics biotechs are more teammates than rivals
MapLight to discuss future of autism drug with FDA despite Phase 2 disappointment
Another big deal, another sign biotech M&A is back
Definium Therapeutics said that its LSD therapy helped patients with major depression in its first Phase 3 trial, bringing the…
People taking Definium Therapeutics' DT120 showed long-lasting reductions in their depression symptoms compared to a placebo, the…
Definium's LSD drug DT120 hit its Phase 3 MDD primary endpoint, beating analyst expectations with significant improvement in…
DT120, a psychedelic that activates serotonin receptors, was generally well tolerated, with mostly mild side effects occurring on…
One analyst called this a "best-case" scenario for the company's experimental depression treatment.
News and commentary from the psychiatry world
